Dyne Therapeutics (DYN) Reiterated at Overweight by Cantor Fitzgerald on Ph1/2 Data Release

September 30, 2026 7:00 AM EDT Send to a Friend
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Dyne Therapeutics (NASDAQ: DYN).The analyst commented, "Dyne released additional 1-year ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login